无巨细胞的H3F3A突变骨巨细胞瘤三例临床、影像与组织学分析
该研究分析三例无多核巨细胞的H3F3A突变骨肿瘤的临床病史、影像、分子病理和组织学,患者均未接受地诺单抗治疗。三例均显示纤维细胞样卵圆细胞伴骨样基质且CD68免疫组化确认无巨细胞,Sanger测序证实H3.3 p.G34W突变。作者认为此类无巨细胞病变扩展了GCTB的异质性谱系,检测H3F3A突变对确诊至关重要。
要点
- 无巨细胞的骨病变需警惕GCTB,组织学 alone 难以确诊。
- H3.3 p.G34W免疫组化或测序有助于无巨细胞GCTB的诊断。
- 三例均无多核巨细胞,CD68免疫组化阴性,伴纤维细胞样卵圆细胞和骨样基质。
核心结论
- 无巨细胞的H3F3A突变骨肿瘤扩展了GCTB的异质性范围。
- 缺乏巨细胞时仅凭组织学诊断GCTB困难甚至不可能。
- 检测特征性H3F3A突变(G34W特异性抗体RM263或测序)对无巨细胞病变的诊断极有帮助。
研究设计与样本
- 对三例无巨细胞的H3F3A突变骨肿瘤进行临床病史、影像、分子病理和组织学分析。
- 诊断材料通过刮除或切除和/或活检获取。
- 患者均未接受地诺单抗治疗。
主要发现
- 三例病变共同组织形态学特征为纤维细胞样卵圆细胞位于骨样基质背景中,且CD68免疫组化确认无多核巨细胞。
- 免疫组化和Sanger测序显示H3.3 p.G34W突变阳性。
- 基于组织形态学、免疫组化和荧光原位杂交系统排除了鉴别诊断。
- 文中展示并讨论了三例的影像学(X线、CT和MRI)。
关键数值与推荐
- GCTB组织学定义为含反应性巨细胞和肿瘤性单核细胞群的病变。
- 高达92%的GCTB病例具有特定的组蛋白基因H3F3A突变。
- 细胞组成范围从巨细胞丰富到巨细胞稀少。
- 需排除的鉴别诊断包括动脉瘤样骨囊肿、非骨化性纤维瘤、软骨母细胞瘤、棕色瘤和巨细胞丰富型骨肉瘤。
临床怎么用
- 对无巨细胞的骨病变,应检测H3F3A突变(G34W特异性抗体RM263或测序)以辅助诊断GCTB。
- 组织学评估需结合免疫组化(如CD68)确认巨细胞缺失。
- 影像学(X线、CT、MRI)可用于辅助评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Giant cell tumour of bone (GCTB) is histologically defined as a lesion containing reactive giant cells and a neoplastic mononuclear cell population; in up to 92% of cases, GCTB is characterised by a specific mutation of the histone gene H3F3A. The cellular composition ranges from giant-cell-rich to giant-cell-poor. The diagnosis of GCTB can be challenging, and several other lesions need to be excluded, e.g. aneurysmal bone cysts, non-ossifying fibromas, chondroblastomas, brown tumours, and giant-cell-rich osteosarcomas. Our aim was to analyse the clinical history, imaging, molecular pathology and histology of three H3F3A-mutated bone tumours without detectable giant cells. None of the patients received denosumab therapy. METHODS AND RESULTS: Diagnostic material was obtained by curettage or resection and/or biopsy. Common histomorphological features of all three reported lesions were fibrocytic, oval cells in a background of osteoid and an absence of multinuclear giant cells as confirmed with CD68 immunohistochemistry. We used immunohistochemistry and Sanger sequencing to demonstrate positivity for the H3.3 p.G34W mutation. Differential diagnoses were systematically excluded on the basis of histomorphology, immunohistochemistry, and fluorescence in-situ hybridisation. The imaging (radiography, computed tomography, and magnetic resonance imaging) for all three cases is presented and discussed. CONCLUSIONS: We believe that these GCTBs without giant cells expand one end of the heterogeneous range of GCTB. Because of the lack of giant cells, correct diagnosis of GCTB is challenging or even impossible on histological grounds alone. In these cases, detection of the characteristic H3F3A mutation (G34W-specific antibody RM263 or sequencing) is extremely helpful for diagnosing those lesions without giant cells as giant cell tumours of bone.
引用
- Leinauer B, Wolf E, Werner M, et al. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases. Histopathology. 2021. PMID: 33991114. doi:10.1111/his.14401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。